Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts

Merus (NASDAQ:MRUS) has been given a consensus recommendation of “Buy” by the sixteen brokerages that are presently covering the company, Marketbeat reports. Fourteen analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $85.92.

Several equities research analysts have issued reports on MRUS shares. The Goldman Sachs Group started coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, December 2nd. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, December 9th. Wells Fargo & Company initiated coverage on shares of Merus in a research report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective for the company. Finally, Piper Sandler initiated coverage on shares of Merus in a research report on Thursday. They issued an “overweight” rating and a $84.00 price objective for the company.

Merus Trading Down 0.2 %

Shares of MRUS stock opened at $40.20 on Friday. Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The firm’s fifty day moving average price is $41.55 and its two-hundred day moving average price is $47.17. The firm has a market capitalization of $2.75 billion, a P/E ratio of -10.18 and a beta of 1.11.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its stake in Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 300 shares in the last quarter. Avior Wealth Management LLC acquired a new position in shares of Merus in the 4th quarter valued at approximately $76,000. nVerses Capital LLC raised its position in shares of Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares in the last quarter. US Bancorp DE acquired a new position in shares of Merus in the 3rd quarter valued at approximately $103,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares in the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.